¡¾Destiny Pharma-Product XF-73¡¿Phase 2b trial of XF-73 Completes Recruitment
2021-01-05 11:50

5th January, 2021 - Destiny Pharma issued an announcement, which is summarized as follows: 

Phase 2b clinical trial of XF-73 completes patient recruitment 

Results expected in Q1 2021

Destiny Pharma today announces that its XF-73 Phase 2b clinical trial was fully recruited by 31 December 2020, meeting the target timeline set for the programme.

Neil Clark, Chief Executive Officer of Destiny Pharma, said: ¡°We are very pleased to have completed enrollment in our Phase 2b clinical trial testing XF-73 nasal gel as a novel product preventing the incidence of post-surgical infections such as MRSA. We previously reported excellent interim safety data in mid-2020 and are now looking forward to announcing the full results of this study and planning the Phase 3 clinical programme. There is a global need for better treatments to prevent post-surgical infections in hospitals as recognized in the FastTrack status awarded to XF-73 by the US FDA. There is also a significant commercial opportunity for XF-73 in the hospital setting which we estimate could generate peak annual product sales of $1 billion in the US alone.

The news today on our XF-73 Phase 2b study is another major milestone for the Company and we continue to look forward to announcing the study results in Q1 2021.¡±

Original website Link: